Overview

Study on Allopregnanolone and Depression in Perimenopausal Women

Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This study aims to identify how the progesterone metabolite allopregnanolone affects behavior and neurobiology that may underlie perimenopausal depression.
Phase:
Phase 4
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Brexanolone
Pregnanolone